EPISODE · Jun 11, 2026 · 2 MIN
Moving PARP Inhibition Upfront: Why the Phase 3 TALAPRO-3 Trial Rewrites Treatment for HRR-Deficient mCSPC
from TheBrief.Health · host TheBrief.Health
ASCO 2026 data suggest first-line talazoparib plus enzalutamide significantly delays progression in HRR-mutated metastatic prostate cancer, highlighting the growing importance of early genomic testing and biomarker-driven treatment.
What this episode covers
ASCO 2026 data suggest first-line talazoparib plus enzalutamide significantly delays progression in HRR-mutated metastatic prostate cancer, highlighting the growing importance of early genomic testing and biomarker-driven treatment.
NOW PLAYING
Moving PARP Inhibition Upfront: Why the Phase 3 TALAPRO-3 Trial Rewrites Treatment for HRR-Deficient mCSPC
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m